Advanced Targeting Systems has exclusively licensed the Substance P- Saporin (SP-SAP) compound to Cell Targeting Technologies for development as a pharmaceutical agent. ATS and collaborators at University of Minnesota and University of California, San Diego have completed several preclinical studies using SP-SAP and have thus far found it safe and effective in two animal models. The journal Science reported the results of studies in a rat chronic pain model showing that SP-SAP appears to eliminate chronic pain permanently while not interfering with the perception of normal, acute pain sensations. Cell Targeting Technologies will raise capital to fund in-depth toxicology studies and plans to bring SP- SAP to clinical trial within the next two years.